<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956419</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8008-302</org_study_id>
    <nct_id>NCT04956419</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Fluconazole Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis (VVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole&#xD;
      In Subjects with Acute vulvovaginal Candidiasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Fluconazole Controlled, Multicenter Phase III Clinical Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with therapeutic cure</measure>
    <time_frame>Day 28</time_frame>
    <description>defined as absence of signs and symptoms of VVC plus negative culture of vaginal swabs for growth of Candida species</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects therapeutic cure</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with clinical cure</measure>
    <time_frame>Day 14 and Day 28</time_frame>
    <description>defined as absence of signs and symptoms of VVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with mycological cure</measure>
    <time_frame>Day 14 and Day 28</time_frame>
    <description>defined as negative culture of vaginal swabs for growth of Candida species</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in VVC signs and symptoms score</measure>
    <time_frame>Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects receiving rescue therapy during the study</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Acute Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR8008 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluconazole capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR8008 capsule</intervention_name>
    <description>once daily for 2 days(Day 1 and Day 2),oral</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole capsule</intervention_name>
    <description>once daily for 2 days(Every 72 hours) ,oral</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females ≥18 and ≤75 years old;&#xD;
&#xD;
          2. Clinical diagnosis with VVC episodes at screening, signs and symptoms score of ≥ 7,&#xD;
             with a documented positive potassium hydroxide (KOH) or Gram staining;&#xD;
&#xD;
          3. Subjects of childbearing potential must have a negative pregnancy test result at&#xD;
             screening and agree to use highly effective contraceptive measures throughout the&#xD;
             study;&#xD;
&#xD;
          4. Willing to sign the informed consent form to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have recurrent vulvovaginal candidiasis (RVVC) as defined by 4 or more confirmed VVC&#xD;
             episodes in the past 12 months or history of RVVC;&#xD;
&#xD;
          2. Presence of concomitant vulvovaginitis caused by other pathogens;&#xD;
&#xD;
          3. History of cervical cancer, or &quot;cervical intraepithelial neoplasia or malignancy&quot; or&#xD;
             &quot;atypical squamous cells of undetermined significance (ASCUS)&quot; as indicated by Pap&#xD;
             test or other tests reported within 1 year before screening;&#xD;
&#xD;
          4. Moderate to severe hepatic and/or renal disorders;&#xD;
&#xD;
          5. Have received systemic or vulvovaginal antifungal drugs, antibacterials,&#xD;
             antitrichomonal, CYP3A4 substrates or inducers or inhibitors, or vulvovaginal&#xD;
             corticosteroids within 7 days prior to randomization;&#xD;
&#xD;
          6. Have received any estrogen replacement therapy or vaginal topical products within 7&#xD;
             days prior to randomization;&#xD;
&#xD;
          7. Have received systemic corticosteroid therapy within 30 days or systemic&#xD;
             immunosuppressant therapy within 90 days prior to randomization;&#xD;
&#xD;
          8. Presence of significant laboratory abnormalities at screening;&#xD;
&#xD;
          9. QTc interval greater than 470 ms or other clinically significant ECG abnormalities at&#xD;
             screening;&#xD;
&#xD;
         10. Have planned surgeries or other medical procedures that may impact compliance with the&#xD;
             protocol;&#xD;
&#xD;
         11. Known history of hypersensitivity or intolerance to azole antifungal drugs;&#xD;
&#xD;
         12. Being in the menstrual period, pregnant, or lactating at screening, or planning to&#xD;
             become pregnant during the study period;&#xD;
&#xD;
         13. History of narcotic or drug abuse or alcoholism within 6 months prior to screening;&#xD;
&#xD;
         14. Have participated in another clinical study and received the investigational drug&#xD;
             containing active ingredient within 30 days prior to screening;&#xD;
&#xD;
         15. Other conditions unsuitable for participation in the study per investigator's&#xD;
             judgment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

